AbbVie Inc. (ABBV) vs State Street SPDR S&P 500 ETF (SPY)

Over the past 10 years, ABBV outperformed SPY — 19.57% vs 14.89% annualized total return (price plus dividends).

A side-by-side comparison of AbbVie Inc. and State Street SPDR S&P 500 ETF across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 28, 2026. Differences are shown without an overall score or investment verdict.

Compare
Different business models: ABBV is classified in Healthcare; SPY is classified in Financial Services. Margin, capital intensity, and valuation differences should be interpreted in that sector context.

Total returnABBV vs SPY

growth of $100 · dividends reinvested · last 14y
ABBV +1164.7%SPY +558.3%ABBV compounded faster
05001kStart $1002015201820212024$1,265$658
ABBV SPY

Metrics side by side

Did ABBV beat SPY?

Over the past 10 years, ABBV outperformed SPY — 19.57% vs 14.89% annualized total return (price plus dividends).

Total return (annualized)

MetricABBVSPY
Total return (1Y)38.99%17.32%
Total return CAGR (3Y)24.19%18.85%
Total return CAGR (5Y)21.24%12.50%
Total return CAGR (10Y)19.57%14.89%

SPY is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Frequently asked

Has ABBV beaten SPY?
Over the past 10 years, ABBV outperformed SPY — 19.57% vs 14.89% annualized total return (price plus dividends).

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 28, 2026.